25H-NBOMe
25H-NBOMe is the unsubstituted parent of the 25x-NBOMe series (N-2-methoxybenzyl-2C-H). It is less potent than its ring-halogenated relatives but is still an active 5-HT2A agonist psychedelic with the same class hazards: narrow margin, vasoconstriction and seizure risk at high doses.
01 Overview
25H-NBOMe lacks the 4-position ring substituent found in 25I/25C/25B, giving it lower 5-HT2A affinity and potency. It has mainly been used as a reference compound and appears only rarely on the recreational market.
Human data are almost nonexistent; the compound is included here for completeness and because its lower potency does not eliminate the characteristic NBOMe toxicity at raised doses. Any use carries the class risks of vasoconstriction and serotonergic overstimulation.
02 Mechanism
Agonist at serotonin 5-HT2A receptors; the N-2-methoxybenzyl group confers 5-HT2A activity on the 2C-H scaffold, though affinity is lower than in halogenated analogues.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common | 1–3 mg | Sublingual | Highly uncertain; anecdotal only. |
| Threshold | 500–1000 µg | Sublingual | Less potent than halogenated NBOMes; still sub-milligram to low-mg. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Mild-moderate psychedelic effectsVisuals and mood/perception change, generally milder than potent NBOMes. | 4-8 h | Anecdotal | |
| StimulationBody activation and tension similar to but weaker than other NBOMes. | mild-moderate | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| VasoconstrictionCold extremities and raised heart rate/blood pressure. | Moderate | Common | Anecdotal | |
| Overstimulation at high dosesAgitation, tremor and, with large overdoses, seizure risk as in the class. | Severe | Uncommon | Anecdotal |